Evidence map›Paper›PMID 26805558›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.

Manon M C Komen, Wim P M Breed, Carolien H Smorenburg, Tjeerd van der Ploeg, S H Goey, Jacobus J M van der Hoeven, Johan W R Nortier, Corina J G van den Hurk

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04678544 (A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04678544 nacompletednot on this mapstarted 2020, after this paper: background citation

A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients

TypeinterventionalSponsorSamsung Medical CenterRan2020 to 2022Enrolled170ConditionsNeoplasm, BreastArmsScalp cooling system 2
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Trial
  2. Trial
  3. Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  4. Observational
  5. Article
  6. Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Observational
  7. Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Manon M C KomenDepartment of Internal Medicine and Medical Oncology, Medical Centre Alkmaar, PO Box 501, 1800, AM, Alkmaar, The Netherlands. manon.komen@mca.nl.
Wim P M BreedGive Hair a Chance Foundation, Research Department, Knowledge Institute Scalp Cooling, PO Box 231, 5600, AE, Eindhoven, The Netherlands.
Carolien H SmorenburgDepartment of Medical Oncology, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Tjeerd van der PloegScience Department, Medical Centre Alkmaar, PO Box 501, 1800, AM, Alkmaar, The Netherlands.
S H GoeyDepartment of Internal Medicine, Twee Steden ziekenhuis, Dr. Deelenlaan 5, 5042, AD, Tilburg, The Netherlands.
Jacobus J M van der HoevenDepartment of Medical Oncology, Leiden University Medical Centre, PO Box 9600, 2300, RC, Leiden, The Netherlands.
Johan W R NortierDepartment of Medical Oncology, Leiden University Medical Centre, PO Box 9600, 2300, RC, Leiden, The Netherlands.
Corina J G van den HurkResearch Department, The Netherlands Comprehensive Cancer Organisation, PO Box 231, 5600, AE, Eindhoven, The Netherlands.
Leiden University Medical Center · NLMedisch Centrum Alkmaar · NLElisabeth-TweeSteden Ziekenhuis · NLNetherlands Comprehensive Cancer Organisation · NLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFor patients, chemotherapy-induced alopecia (CIA) is one of the most distressing side effects of treatment. Scalp cooling can prevent or minimise CIA; the results may depend on the duration of cooling. Since a previous study on post-infusion cooling time in patients treated with docetaxel chemotherapy found no difference between 90 and 45 min, we investigated whether hair-preserving results could be maintained with a shorter post-infusion cooling time.

methodsIn this prospective, multi-centre randomised study, 134 patients who started treatment with docetaxel 75-100 mg/m(2) in a 3-weekly schedule were randomly assigned in a 1:1 ratio to a post-infusion cooling time of 45 or 20 min. The primary end point was the need for a wig or other head covering as assessed by the patient. A visual analogue scale (VAS) with a range from 0 (not tolerable) to 10 (very tolerable) was used to measure tolerance.

resultsScalp cooling results were similar for 45- and 20-min post-infusion cooling times. Thirty-three out of 45 patients (73 %) treated with 20 min of post-infusion cooling did not need a form of head covering, compared with 41 out of 52 patients (79 %) treated with 45 min of post-infusion cooling (p = 0.5). The procedure was well tolerated (mean visual analogue score 8.3). Six patients stopped due to intolerance during the first treatment cycle.

conclusionsA 20-min post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia.

trial registrationTrialregister.nl Identifier, NTR 1856.

Indexed as

ScalpAdultAgedAged, 80 and overAlopeciaAntineoplastic AgentsDocetaxelDrug-Related Side Effects and Adverse ReactionsFemaleHumansHypothermia, InducedMaleMiddle AgedNeoplasmsOutcome Assessment, Health CareProspective StudiesAntineoplastic AgentsDocetaxelTaxoidsAlopeciaChemotherapyDocetaxelScalp coolingSide effects

Identifiers

PMID26805558
OpenAlexW2254058441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.